| 1 |
卢艳敏, 陈强谱. 肌肉减少症的诊断及治疗 [J/OL]. 中华临床医师杂志(电子版), 2014(24): 4454-4457.
|
| 2 |
蔡婷婷, 王蕾, 陈强谱. 肌肉减少症对老年患者术后并发症的影响及干预措施 [J]. 中华老年医学杂志, 2021, 40(8): 971-975.
|
| 3 |
Takada H, Kurosaki M, Nakanishi H, et al. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma [J]. PLoS One, 2018, 13(6): e198812.
|
| 4 |
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析 [J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
|
| 5 |
郑艺. 运动干预支持在老年肌肉减少症病人中应用的研究进展 [J]. 全科护理, 2020, 18(30): 4100-4103.
|
| 6 |
戚倩, 吴蓓雯, 费晓燕. 肿瘤相关性肌肉减少症影响因素的研究进展 [J]. 中国全科医学, 2018, 21(15): 1769-1774.
|
| 7 |
程群, 郑丽丽, 章振林. 肌肉减少症流行病学及发病机制 [J]. 中华骨质疏松和骨矿盐疾病杂志, 2016, 9(3): 228-235.
|
| 8 |
Pamoukdjian F, Bouillet T, Levy V, et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review [J]. Clin Nutr, 2018, 37(4): 1101-1113.
|
| 9 |
Ruiz-Margain A, Roman-Calleja B M, Moreno-Guillen P, et al. Nutritional therapy for hepatocellular carcinoma [J]. World J Gastrointest Oncol, 2021, 13(10): 1440-1452.
|
| 10 |
向谦, 陈丽, 付丹, 等. 肌肉减少症对接受TACE治疗原发性肝癌患者生存期的影响 [J]. 现代消化及介入诊疗, 2021, 26(2): 202-207.
|
| 11 |
Takada H, Kurosaki M, Nakanishi H, et al. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma [J]. PLoS One, 2018, 13(6): e198812.
|
| 12 |
Damanti S, Azzolino D, Roncaglione C, et al. Efficacy of nutritional interventions as stand-alone or synergistic treatments with exercise for the management of sarcopenia [J]. Nutrients, 2019, 11(9): 1991.
|
| 13 |
杨玲, 杜娟, 刘荣雁, 等. 肌肉减少症病因学研究现状与展望 [J]. 中国骨质疏松杂志, 2020, 26(11): 1689-1693.
|
| 14 |
Hamrick M W, McGee-Lawrence M E, Frechette D M. Fatty infiltration of skeletal muscle: mechanisms and comparisons with bone marrow adiposity [J]. Front Endocrinol (Lausanne), 2016, 7: 69.
|
| 15 |
Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma [J]. J Hepatol, 2015, 63(1): 131-140.
|
| 16 |
Buckinx F, Landi F, Cesari M, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard [J]. J Cachexia Sarcopenia Muscle, 2018, 9(2): 269-278.
|
| 17 |
Hamaguchi Y, Kaido T, Okumura S, et al. Preoperative intramuscular adipose tissue content is a novel prognostic predictor after hepatectomy for hepatocellular carcinoma [J]. J Hepatobiliary Pancreat Sci, 2015, 22(6): 475-485.
|
| 18 |
王青青, 苏晓雨, 彭玉晓, 等. 基于CT的骨骼肌参数诊断肿瘤病人肌肉减少症[J]. 国际医学放射学杂志, 2021, 44(3): 324-329.
|
| 19 |
Wu C H, Liang P C, Hsu C H, et al. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma [J]. J Formos Med Assoc, 2021, 120(1 Pt 2): 559-566.
|
| 20 |
Chang K V, Chen J D, Wu W T, et al. Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: a systematic review and meta-analysis [J]. Liver Cancer, 2018, 7(1): 90-103.
|
| 21 |
Marasco G, Serenari M, Renzulli M, et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments [J]. J Gastroenterol, 2020, 55(10): 927-943.
|
| 22 |
Berardi G, Antonelli G, Colasanti M, et al. Association of sarcopenia and body composition with short-term outcomes after liver resection for malignant tumors [J]. JAMA Surg, 2020, 155(11): e203336.
|
| 23 |
Voron T, Tselikas L, Pietrasz D, et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma [J]. Ann Surg, 2015, 261(6): 1173-1183.
|
| 24 |
Hiraoka A, Otsuka Y, Kawasaki H, et al. Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma [J]. J Gastroenterol Hepatol, 2018, 33(6): 1271-1276.
|
| 25 |
王蕾, 卢艳敏, 冀海斌, 等. 肌肉减少症对肝切除术后患者预后影响的Meta分析 [J]. 现代肿瘤医学, 2021, 29(20): 3600-3604.
|
| 26 |
Bajric T, Kornprat P, Faschinger F, et al. Sarcopenia and primary tumor location influence patients outcome after liver resection for colorectal liver metastases [J]. Eur J Surg Oncol, 2021: S0748-7983(21)00736-8.
|
| 27 |
Heil J, Heid F, Bechstein W O, et al. Sarcopenia predicts reduced liver growth and reduced resectability in patients undergoing portal vein embolization before liver resection - A DRAGON collaborative analysis of 306 patients [J]. HPB (Oxford), 2021: S1365-182X(21)01458-1.
|
| 28 |
Denbo J W, Kim B J, Vauthey J N, et al. Overall body composition and sarcopenia are associated with poor liver hypertrophy following portal vein embolization [J]. J Gastrointest Surg, 2021, 25(2): 405-410.
|
| 29 |
Runkel M, Diallo T D, Lang S A, et al. The role of visceral obesity, sarcopenia and sarcopenic obesity on surgical outcomes after liver resections for colorectal metastases [J]. World J Surg, 2021, 45(7): 2218-2226.
|
| 30 |
Hamaguchi Y, Kaido T, Okumura S, et al. Proposal for new selection criteria considering pre-transplant muscularity and visceral adiposity in living donor liver transplantation [J]. J Cachexia Sarcopenia Muscle, 2018, 9(2): 246-254.
|
| 31 |
Kaido T, Tamai Y, Hamaguchi Y, et al. Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation [J]. Nutrition, 2017,33:195-198.
|
| 32 |
Kim Y R, Park S, Han S, et al. Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria [J]. Sci Rep, 2018,8(1):7157.
|
| 33 |
Lanza E, Masetti C, Messana G, et al. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma [J]. PLoS One, 2020, 15(6): e232371.
|
| 34 |
Fujita M, Takahashi A, Hayashi M, et al. Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma [J]. Hepatol Res, 2019, 49(7): 778-786.
|
| 35 |
Kobayashi T, Kawai H, Nakano O, et al. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies [J]. BMC Cancer, 2018, 18(1): 756.
|
| 36 |
Lee J, Cho Y, Park S, et al. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with radiotherapy [J]. Front Oncol, 2019, 9: 1075.
|
| 37 |
Faron A, Sprinkart A M, Pieper C C, et al. Yttrium-90 radioembolization for hepatocellular carcinoma: Outcome prediction with MRI derived fat-free muscle area [J]. Eur J Radiol, 2020, 125: 108889.
|
| 38 |
Kim N, Yu J I, Park H C, et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab [J]. Cancer Immunol Immunother, 2021, 70(6): 1593-1603.
|
| 39 |
Nishikawa H, Nishijima N, Enomoto H, et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy [J]. Oncol Lett, 2017, 14(2): 1637-1647.
|
| 40 |
Qayyum A, Bhosale P, Aslam R, et al. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma [J]. Abdom Radiol (NY), 2021, 46(3): 1008-1015.
|
| 41 |
Bibby N, Griffin O. Nutritional considerations for the management of the older person with hepato-pancreatico-biliary malignanc y [J]. Eur J Surg Oncol, 2021, 47(3 Pt A): 533-538.
|
| 42 |
Nakahara S, Takasaki M, Abe S, et al. Aggressive nutrition therapy in malnutrition and sarcopenia [J]. Nutrition, 2021, 84: 111109.
|
| 43 |
Cogo E, Elsayed M, Liang V, et al. Are supplemental branched-chain amino acids beneficial during the oncological peri-operative period: a systematic review and meta-analysis [J]. Integr Cancer Ther, 2021, 20: 1873215983.
|
| 44 |
Cavallucci V, Pani G. The leucine catabolite and dietary supplement beta-hydroxy-beta-methyl butyrate (HMB) as an epigenetic regulator in muscle progenitor cells [J]. Metabolites, 2021, 11(8).
|
| 45 |
Aubertin-Leheudre M, Buckinx F. Effects of citrulline alone or combined with exercise on muscle mass, muscle strength, and physical performance among older adults: a systematic review [J]. Curr Opin Clin Nutr Metab Care, 2020, 23(1): 8-16.
|
| 46 |
Koya S, Kawaguchi T, Hashida R, et al. Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease [J]. Hepatol Res, 2017, 47(3): E22-E34.
|
| 47 |
Koya S, Kawaguchi T, Hashida R, et al. Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization [J]. J Gastroenterol Hepatol, 2019, 34(3): 580-588.
|
| 48 |
Davis M P, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy [J]. Ann Palliat Med, 2019, 8(1): 86-101.
|
| 49 |
Gkekas N K, Anagnostis P, Paraschou V, et al. The effect of vitamin D plus protein supplementation on sarcopenia: A systematic review and meta-analysis of randomized controlled trials [J]. Maturitas, 2021, 145: 56-63.
|
| 50 |
Ebner N, Anker S D, von Haehling S. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 12th Cachexia Conference [J]. J Cachexia Sarcopenia Muscle, 2020, 11(1): 274-285.
|